



JFW

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In Re the Application of:

Verkerk et al.

Serial No.: 10/585,792

Filed: July 12, 2006

Atty. File No.: 1704 WO/US

Title: Improvement in the Ligand Protection  
For Mercaptoacetyl Triglycine

) Group Art Unit: Not yet assigned

) Examiner: Not yet assigned

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING MAILED USING THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL TO: COMMISSIONER  
OF PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-  
1450 ON AUGUST 3, 2006.

  
MICHELLE DE CORTE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

In accordance with duties imposed by 37 CFR §1.56 and means for complying therewith according to 37 CFR §§1.97-1.98, the references listed on the attached Form PTO/SB/08A are called to the attention of the US Patent & Trademark Office in relation to the present application.

No representation is made that the cited references are the only art or that the cited references represent the best art. The Examiner is urged to consider all of the cited references and to make an independent evaluation of the teachings and materiality of each.


Since this correspondence is being submitted prior to a first Office Action on the merits, it is believed that no fee is due. However, if a fee is required for entry of this correspondence, please charge the appropriate fee to Deposit Account No. 13-1160.

Respectfully submitted,

  
Jerad G. Seurer (Reg. No. 45,467)  
jerad.seurer@tycohealthcare.com  
314-654-3814

2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	10/585,792
Filing Date	July 12, 2006
First Named Inventor	VERKERK
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	1704 WO/US

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A1	EP 0483704	05-06-1992	KONDO, et al.		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B2	STALTERI, et al., Comparison of the Stability of Technetium-Labeled Peptides to Challenge with Cysteine, Bioconjugate Chemistry, American Chemical Society, , January 1999, Vol. 10, No. 1, pgs. 130-136 XP009003810	
	B3	NOLL, et al., Sources of radiochemical impurities in the <sup>99m</sup>TcS-unprotected MAG3 system, Nuclear Medicine and biology, Elsevier Science Publishers, November 1995, Vol. 22, No. 8, pgs. 1057-1062 XP004051713	
	B4	BORMANS, et al., Investigation of the Labelling Characteristics of <sup>99m</sup>/tc-Mercaptoacetyl triglycine" Nuclear Medicine and biology, April 1995, Vol. 22, No. 3, pgs. 339-349, XP004051796	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.